Buy Retrovir (Zidovudine, AZT) Online — Historic First Antiretroviral FDA-Approved (1987) for HIV-1 Infection, PMTCT & Post-Exposure Prophylaxis

Retrovir is the original brand-name formulation of zidovudine (also known as AZT or ZDV), one of the most historically significant antiretroviral medications ever developed. On March 19, 1987, Retrovir became the first antiretroviral agent approved by the FDA for HIV infection. The 21-month approval process from investigational new drug application to marketing authorization was the fastest in FDA history at that time, reflecting the urgent need for HIV therapy during the peak of the AIDS crisis. Originally developed by Burroughs Wellcome, the Retrovir brand is now within the ViiV Healthcare HIV portfolio.

Zidovudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class of antiretrovirals. Chemically, it is a thymidine analog with an azido group at the 3-prime position of the sugar ring. This structural feature blocks viral DNA chain elongation and provides its antiviral activity. Although zidovudine has been largely superseded by better-tolerated NRTIs in modern initial HIV therapy, it retains an important role in perinatal HIV prevention and specific other applications discussed throughout this guide.

Modern positioning: since better-tolerated NRTIs (tenofovir, abacavir, lamivudine, emtricitabine) became available, zidovudine has retreated from first-line HIV therapy in most settings. However, it retains specific important roles: perinatal HIV prevention (where extensive safety data supports use during pregnancy and in newborn prophylaxis), Combivir fixed-dose combination with lamivudine for specific patient populations, and use in resource-limited settings where alternative NRTIs may be less accessible. Zidovudine remains on the WHO Model List of Essential Medicines.

The story of zidovudine is one of the most remarkable in pharmaceutical history. A molecule synthesized in 1964 as a failed cancer drug was rediscovered two decades later, tested against a newly identified virus (HIV), and rushed through the fastest FDA approval process ever completed at that time. The story spans academic chemistry, oncology research, virology, industry development, and public health advocacy during the peak of the AIDS crisis.

Historical significance beyond the drug itself: zidovudine approval transformed HIV from a rapidly fatal condition into a treatable disease, laying the foundation for the modern era of chronic HIV management. The urgent 21-month FDA approval process influenced subsequent regulatory approaches to serious life-threatening diseases. The ACTG 076 perinatal trial has been credited with preventing hundreds of thousands of infant HIV infections globally. Even as zidovudine has been superseded in initial adult therapy, its historical impact on the trajectory of the HIV pandemic is difficult to overstate.

Zidovudine is chemically a modified thymidine nucleoside. The molecule replaces the 3-prime hydroxyl group of natural thymidine deoxyribose with an azido group (three linked nitrogen atoms). This substitution is the key structural feature that enables the antiviral chain termination mechanism discussed in the next section. The full chemical name azidothymidine gave rise to the widely used abbreviation AZT.

Formulations available: Retrovir 100 mg capsules and 300 mg tablets for oral HIV therapy in adults and older children; Retrovir 50 mg/5 mL oral solution (10 mg/mL) for pediatric dosing and neonatal perinatal prophylaxis; Retrovir 10 mg/mL intravenous solution for peripartum administration during labor and in patients unable to take oral therapy. Multiple generic zidovudine formulations are available worldwide at accessible prices.

Bioequivalence: generic zidovudine formulations from multiple manufacturers have demonstrated bioequivalence to the Retrovir innovator product through standard pharmacokinetic studies. WHO Prequalification of generic zidovudine including from Cipla and other Indian manufacturers supports global procurement for national HIV programs, particularly for perinatal HIV prevention in resource-limited settings.

Zidovudine works by inhibiting HIV reverse transcriptase, the viral enzyme that copies HIV RNA genome into DNA during early replication. As a thymidine analog, zidovudine triphosphate competes with the natural nucleotide thymidine triphosphate (TTP) at the reverse transcriptase active site. Once incorporated into the growing viral DNA strand, the 3-prime azido group prevents further chain elongation - obligate chain termination that halts HIV replication.

Why zidovudine is never used as monotherapy in modern HIV therapy: HIV replication rates and mutation frequency mean that single-drug therapy predictably selects for resistance and treatment failure. Zidovudine monotherapy in the pre-HAART era achieved only modest transient benefit before viral rebound. Modern practice requires combination therapy with at least two mechanistically distinct antivirals to prevent resistance emergence. Zidovudine, when used, is always part of a combination regimen.

Zidovudine antiviral spectrum: primarily HIV-1 activity. Limited activity against HIV-2. No meaningful activity against HBV (unlike its structural relative in some combinations, lamivudine). No activity against non-retroviral pathogens. This narrow spectrum focuses zidovudine role on HIV specifically.

Zidovudine pharmacokinetics are characterized by rapid absorption, extensive first-pass metabolism via glucuronidation, renal excretion of parent drug and inactive glucuronide metabolite, and intracellular phosphorylation to the active triphosphate form. The intracellular triphosphate half-life is longer than the plasma parent drug half-life, supporting the twice-daily dosing framework.

Intravenous administration option: zidovudine has an intravenous formulation used historically for patients unable to take oral therapy and specifically during labor for perinatal HIV prevention (per historical ACTG 076 protocol). The intravenous route achieves rapid, predictable systemic exposure important for time-limited interventions like the peripartum period.

Zidovudine FDA-approved indications span HIV treatment in adults and pediatric patients, perinatal HIV prevention (both maternal antepartum use and neonatal prophylaxis), and historically post-exposure prophylaxis for occupational HIV exposure. All treatment indications require combination therapy with at least one additional antiretroviral. Perinatal prevention use may involve zidovudine as a specific component of maternal antiretroviral regimen and separately for infant prophylaxis.

Modern practice reality: while formally approved for HIV treatment in adults, zidovudine is not preferred for initial adult HIV therapy in modern practice due to its adverse effect profile (particularly bone marrow suppression) compared to newer NRTIs. Current DHHS, IAS-USA, EACS, and BHIVA guidelines recommend tenofovir or abacavir as preferred NRTI backbone components, with zidovudine reserved for specific scenarios such as perinatal prevention, resource-limited settings where alternatives are unavailable, or Combivir fixed-dose combination use.

Specific scenarios where zidovudine retains relevance: perinatal HIV prevention (extensive safety database supports use in pregnancy); Combivir (zidovudine + lamivudine) fixed-dose combinations in specific national programs; neonatal prophylaxis (well-established protocols); occupational post-exposure prophylaxis in resource-limited settings; some settings where alternative NRTIs cannot be dose-adjusted for renal impairment. These focused applications support zidovudine continued availability.

Zidovudine has been part of HIV combination therapy across multiple eras. The molecule has been paired with essentially every class of antiretroviral over the past three decades of HIV therapy evolution. Understanding these historical combinations provides context for zidovudine current specialized role and for the fixed-dose combination products that remain in use.

Why zidovudine gradually retreated from routine use: as tenofovir (2001) and other better-tolerated NRTIs became widely available, comparative trials favored these newer agents for lower toxicity. The bone marrow suppression, myopathy, and lipoatrophy associated with zidovudine progressively became less acceptable when alternatives with cleaner profiles were available. This transition was completed in high-income settings by approximately 2010; resource-limited settings maintained zidovudine use longer due to cost and availability considerations.

Modern zidovudine-containing regimens: primarily Combivir (zidovudine + lamivudine 300/150 mg fixed-dose combination) used in some settings, and zidovudine alone as component of perinatal prophylaxis regimens. Sections 8 (perinatal), 10 (modern positioning), and 11 (Combivir/Trizivir) discuss these current applications in detail.

The ACTG 076 landmark trial published by Connor et al. in 1994 represents one of the most important pediatric HIV research findings ever reported. This placebo-controlled trial demonstrated that zidovudine reduced perinatal HIV transmission from mother to infant by approximately two-thirds - from a baseline rate of about 25% down to about 8%. The findings transformed maternal-child HIV care globally and established zidovudine as the foundation of perinatal HIV prevention.

Zidovudine specific advantages for perinatal use: extensive placental transfer (approximately 85% of maternal plasma concentration reaches fetal circulation) provides protective drug levels in the fetus. Extensive human safety data spanning 30+ years of perinatal use confirms acceptable safety profile in pregnancy and infancy. Well-established neonatal dosing and administration protocols. Availability of oral syrup formulation appropriate for newborns. WHO Prequalified generic availability supports resource-limited setting use.

Post-exposure prophylaxis (PEP) refers to antiretroviral treatment given after potential HIV exposure to prevent seroconversion. Zidovudine has been used historically in PEP protocols since the late 1980s, though modern PEP practice generally uses newer antiretrovirals. Understanding the historical zidovudine role and current PEP framework helps contextualize zidovudine ongoing availability.

Modern PEP practical framework: assess exposure risk and source status; initiate 3-drug PEP within 72 hours (ideally within 2 hours); complete 28-day course; HIV testing at baseline, 4-6 weeks, 3 months, and 6 months post-exposure. Modern PEP regimens have excellent tolerability, high adherence rates, and demonstrated efficacy. Zidovudine remains available as a component option when clinical circumstances favor its use.

Modern zidovudine positioning in HIV therapy is focused and specific rather than broadly first-line. While historically the foundation of HIV combination therapy, zidovudine has retreated to specialized roles as better-tolerated NRTIs have become available. Understanding current positioning helps clinicians and patients navigate treatment decisions in the modern era.

Global regional variation: zidovudine use is much more common in some regions than others based on local guidelines, generic availability, and cost considerations. National HIV programs balance efficacy, tolerability, cost, and drug availability. Cipla and other Indian manufacturers provide inexpensive generic zidovudine that supports continued availability in resource-limited settings.

Future trajectory: as tenofovir alafenamide and other well-tolerated NRTIs become more widely available globally, zidovudine role in adult HIV treatment may contract further. However, its specific perinatal prevention application is likely to persist given the extensive safety database. Zidovudine will remain on WHO Essential Medicines List for the foreseeable future given its historical importance and continued specialized applications.

Zidovudine has been formulated in two important fixed-dose combination products: Combivir (zidovudine + lamivudine) approved in 1997 and Trizivir (zidovudine + lamivudine + abacavir) approved in 2000. These combinations simplified HIV therapy by reducing pill burden. Combivir remains available and used in some settings; Trizivir has been largely superseded by better options but retains niche applications.

Modern trajectory for fixed-dose combinations: zidovudine-containing combinations have largely been displaced by tenofovir-based combinations like Truvada (tenofovir + emtricitabine) and Descovy (tenofovir alafenamide + emtricitabine), plus single-tablet regimens like Biktarvy, Genvoya, and Symtuza that include integrase inhibitors. Zidovudine-containing Combivir remains as a well-tolerated alternative in specific circumstances.

Zidovudine remains widely used in resource-limited settings where cost, availability, and infrastructure considerations differ from high-income countries. The extensive generic availability, WHO Essential Medicines status, established safety database, and continued relevance for perinatal prevention support ongoing use in national HIV programs across Africa, Asia, and Latin America.

Access advocacy and Cipla legacy: as with hepatitis C sofosbuvir generics, HIV generic manufacturing by Indian companies including Cipla has been central to global HIV treatment scale-up. Cipla was the first company to offer generic combination antiretroviral therapy at approximately 1 USD per patient per day in 2001, transforming HIV treatment access in Africa. This access-oriented approach applied to both zidovudine-based and newer tenofovir-based regimens has been essential to progress toward UNAIDS 95-95-95 treatment targets.

Future outlook: zidovudine role in resource-limited settings will likely continue to contract as tenofovir-based combinations become more universally available. However, perinatal HIV prevention applications, second-line alternatives, and settings where newer options remain inaccessible will support continued zidovudine availability. WHO Essential Medicines status and Cipla generic manufacturing support this continued supply.

Adult zidovudine dosing for HIV treatment is a twice-daily oral regimen. The standard adult dose is 300 mg twice daily, historically expressed as 200 mg three times daily in earlier protocols. Combination therapy with at least one additional antiretroviral is mandatory - zidovudine monotherapy is never appropriate for HIV treatment given rapid resistance emergence. Combivir (zidovudine 300 mg + lamivudine 150 mg twice daily) simplifies dosing when this combination is selected.

Modern combination regimen options including zidovudine typically involve Combivir (zidovudine + lamivudine) as the NRTI backbone plus a third agent such as dolutegravir (integrase inhibitor), efavirenz (NNRTI, historical), or lopinavir/ritonavir (boosted PI, historical). Trizivir (single-tablet triple NRTI) is available but essentially never used as first-line therapy due to inferior efficacy compared to modern alternatives.

When Combivir is preferred over separate components: pill burden reduction supports adherence; fixed-dose combination ensures both NRTIs are taken together; standard 300/150 mg twice daily fits most adult patients. Combivir cannot be dose-adjusted for renal impairment - patients requiring dose adjustment must switch to separate zidovudine and lamivudine formulations with individualized dosing.

Pediatric zidovudine dosing spans from birth (neonatal prophylaxis) through adolescence using weight-based calculations. Neonatal prophylaxis for infants born to HIV-positive mothers is arguably zidovudine most important current application. Pediatric HIV treatment dosing extends from infants through adolescents with weight-based schedules. The oral syrup formulation enables accurate dosing in the smallest patients.

Palatability: Retrovir syrup has a strawberry flavor that most infants accept. In infants who resist administration, mixing with small amounts of breast milk or formula in an oral syringe usually enables acceptance. Adequate hydration during any diarrheal illness is particularly important in young infants.

Pediatric adverse effect monitoring: infants and children experience the same zidovudine adverse effects as adults - primarily anemia and neutropenia from bone marrow suppression. Baseline and periodic CBC monitoring is standard. Growth impact during prolonged pediatric zidovudine therapy is monitored via standard growth curves.

Older adult zidovudine prescribing requires attention to anemia tolerance, renal function, and cardiovascular comorbidities. The bone marrow suppression from zidovudine can be particularly consequential in older adults who tolerate anemia poorly due to reduced cardiovascular reserve. Modern HIV therapy in older adults generally uses newer NRTIs (tenofovir, abacavir) rather than zidovudine when clinically appropriate.

No specific age-based dose adjustment is required for zidovudine. Dose modifications are based on renal function, hematologic parameters, and comorbidities rather than chronologic age. This reflects the drug pharmacology which does not change meaningfully with normal aging beyond the renal function considerations.

Existing patients on zidovudine: older adults who have been on stable zidovudine-containing regimens for years with good tolerability and virologic control often continue their regimen. Regimen switching for switching sake is not usually indicated. However, emergence of anemia, cardiac disease, or other tolerability issues may prompt consideration of transition to alternative NRTIs.

Because zidovudine and its glucuronide metabolite are eliminated primarily through the kidneys, severe renal impairment requires dose adjustment. Unlike tenofovir which has complex renal considerations, zidovudine dose adjustment for renal impairment is relatively straightforward with clear thresholds. Fixed-dose combinations containing zidovudine (Combivir, Trizivir) cannot be dose-adjusted separately and require substitution with individual components when adjustment is needed.

Monitoring in renal impairment: more frequent hemoglobin and CBC monitoring - weekly for first month after dose adjustment, then every 2 weeks. Assess for symptomatic anemia. Coordinate with nephrology for dialysis patients. Consider alternative NRTIs (abacavir with HLA-B*5701 testing, or specific tenofovir formulations with appropriate consideration) if zidovudine-related hematologic issues emerge.

Post-transplant renal considerations: renal transplant recipients with HIV can receive zidovudine-containing regimens with attention to interactions with immunosuppressants. Cyclosporine and tacrolimus do not have major zidovudine interactions. Coordination between transplant nephrology and HIV specialists supports appropriate care.

Zidovudine undergoes extensive hepatic glucuronidation via UGT2B7. Hepatic impairment can therefore increase zidovudine exposure, though clear dose adjustment guidance is limited. Clinical judgment and enhanced monitoring apply in severe hepatic impairment. Fortunately, most HIV patients requiring hepatic considerations have concurrent HCV or HBV coinfection rather than isolated hepatic disease, and modern HCV cure with sofosbuvir-based DAAs has substantially reduced the population with active hepatic dysfunction.

Pre-treatment hepatic assessment: comprehensive metabolic panel with hepatic enzymes and albumin; PT/INR; assessment for hepatic steatosis, cirrhosis, or coexisting viral hepatitis; HCV RNA and HBsAg testing. Baseline abnormalities may warrant hepatology consultation before initiating zidovudine.

Post-cure liver function trajectory: HIV/HCV coinfected patients cured of HCV often experience improved hepatic function over subsequent months. Cirrhotic patients require ongoing hepatology follow-up. Zidovudine can typically be continued or initiated in cured HIV/HCV coinfected patients based on overall HIV therapy considerations.

Zidovudine drug interactions center on additive bone marrow suppression with other myelosuppressive agents and glucuronidation pathway interactions with drugs affecting UGT2B7. Overall the interaction profile is relatively favorable, with the main clinical concerns being predictable additive hematologic effects and specific interactions worth reviewing before combination use.

Notably manageable: zidovudine has no clinically significant interactions with common oral contraceptives, most statins, common antihypertensives, oral antidiabetic agents, or the typical medications used in chronic disease management. Interactions with modern integrase inhibitors (dolutegravir, bictegravir, raltegravir) and most NNRTIs are manageable. Most patients on stable medication regimens can add zidovudine without medication changes beyond the specific concerns above.

Zidovudine has one of the most extensive pregnancy safety databases in the antiretroviral pharmacopeia. Nearly four decades of use in HIV therapy and prevention of mother-to-child transmission have generated substantial evidence supporting its safety across all trimesters. Both the Antiretroviral Pregnancy Registry and multiple observational cohort studies confirm that zidovudine exposure does not increase congenital malformation risk above baseline population rates.

Dolutegravir first-line status resolved: earlier signals of possible neural tube defects with periconceptional dolutegravir exposure (Tsepamo study Botswana) have been reconsidered as follow-up data accumulated. Current WHO and DHHS guidelines fully support dolutegravir use in pregnancy, and tenofovir + emtricitabine + dolutegravir is the preferred first-line regimen. Zidovudine is thus not the preferred component but remains available if clinical circumstances favor its use.

Practical framework: assess pregnancy status in HIV-positive women aged 15-50 before starting therapy. Preferred modern regimen is tenofovir + emtricitabine + dolutegravir. Zidovudine-containing alternatives may be used when preferred agents are contraindicated or unavailable. Extensive safety database supports zidovudine use throughout pregnancy when needed.

Breastfeeding recommendations for HIV-positive mothers differ substantially by geographic and epidemiological setting. Zidovudine passes into breast milk in measurable amounts. The primary decision framework centers on whether breastfeeding is recommended at all in the specific clinical scenario, with zidovudine safety in the breastfed infant a secondary consideration once the breastfeeding decision is made.

Infant monitoring during maternal antiretroviral therapy: infants breastfed by HIV-positive mothers receive continued HIV testing at established intervals until 6-12 weeks after complete cessation of breast milk exposure. Some settings include continued infant antiretroviral prophylaxis throughout breastfeeding. Both approaches reduce vertical transmission substantially compared to no intervention, though breastfeeding avoidance where feasible remains the safest strategy.

Neonatal prophylaxis regardless of feeding choice: all infants born to HIV-positive mothers receive neonatal zidovudine prophylaxis for 4-6 weeks after birth regardless of subsequent feeding choice. This standard protocol is separate from maternal breast milk considerations and reflects the primary utility of neonatal zidovudine for preventing perinatal HIV acquisition.

Zidovudine has a more extensive adverse effect profile than modern NRTIs (tenofovir, abacavir, emtricitabine, lamivudine). Bone marrow suppression is the dominant tolerability concern. Gastrointestinal effects and headache are also common. Mitochondrial toxicity manifestations (myopathy, lipoatrophy, rare lactic acidosis) reflect zidovudine effects on mitochondrial DNA polymerase gamma. Understanding this profile shapes appropriate patient selection and monitoring.

Discontinuation rates for tolerability: substantially higher than for modern NRTIs. In real-world cohorts, zidovudine tolerability-driven modification occurs in 10-20% of patients within the first year of therapy. This contrasts with much lower rates for tenofovir, abacavir, or emtricitabine. Where alternatives are available and appropriate, they are typically preferred.

Persistence in specific applications: despite tolerability challenges, zidovudine retains its role in perinatal prevention (where the extensive safety database and neonatal experience outweigh alternatives) and specific scenarios where alternative NRTIs cannot be used. Ongoing use in resource-limited settings reflects cost and availability considerations balancing against tolerability.

The following sections provide detailed coverage of specific adverse effect categories for zidovudine. This landing overview provides orientation for navigating sections 23-33 (specific categories), 34 (monitoring), 35 (counseling), and 36 (contraindications). Given zidovudine more extensive adverse effect profile compared to modern NRTIs, this navigation guide helps direct attention to the categories most relevant to individual patient circumstances.

Key takeaway: zidovudine has a more extensive adverse effect profile than modern NRTIs but the profile is well-characterized after four decades of clinical use. The two dominant concerns - bone marrow suppression and mitochondrial toxicity spectrum (myopathy, lipoatrophy, and rare lactic acidosis) - shape modern preference for newer NRTIs when clinically feasible. Zidovudine retains specific applications where its extensive safety database (particularly perinatal) outweighs alternatives. Standard monitoring identifies problems early when they arise.

How to use the sections ahead: sections 23-33 provide focused coverage of specific adverse effects. Section 23 addresses bone marrow suppression in depth. Section 24 covers the NRTI class lactic acidosis boxed warning. Subsequent sections address individual categories. Sections 34-36 cover monitoring, counseling, and contraindications. Individual patient experience varies substantially, and standard monitoring identifies problems early when they arise.

Bone marrow suppression is the dose-limiting toxicity of zidovudine and the most important non-pregnancy safety consideration. Zidovudine incorporates into mitochondrial DNA of rapidly dividing bone marrow progenitor cells, disrupting hematopoiesis and producing progressive anemia and neutropenia. This mitochondrial toxicity mechanism explains why bone marrow effects are more prominent with zidovudine than with modern NRTIs that spare mitochondrial DNA polymerase gamma.

Monitoring schedule: baseline CBC before starting; week 2 and week 4 initial monitoring; monthly for the first 3 months; then every 3-6 months if stable. More frequent monitoring in patients with advanced HIV disease (baseline CD4 under 200), baseline anemia, concurrent bone marrow suppressants, or after dose modification.

The NRTI class boxed warning for lactic acidosis and severe hepatomegaly with steatosis applies to zidovudine and other NRTIs including didanosine and stavudine most prominently. Zidovudine mitochondrial DNA polymerase gamma affinity is the mechanistic basis. Although rare with modern reduced-dose zidovudine, this warning represents an important safety consideration requiring recognition and immediate response when it occurs.

Immediate discontinuation of all NRTIs is warranted when lactic acidosis is suspected. Supportive care in intensive care unit setting may be needed for severe cases. Some cases have required continuous renal replacement therapy to clear the acid load. Recovery can take weeks to months even after drug discontinuation because mitochondrial recovery is slow. Case-fatality rates for full syndromic lactic acidosis have historically been substantial, though these events are now rare with modern NRTI selection.

Modern context: severe lactic acidosis with NRTI use is now rare, largely because stavudine and didanosine (the highest-risk agents) have been withdrawn and zidovudine use has contracted. Modern regimens using tenofovir, abacavir, lamivudine, or emtricitabine have very low lactic acidosis risk. However, the boxed warning remains as an important label consideration for any patient receiving zidovudine.

Myopathy is a characteristic zidovudine adverse effect reflecting mitochondrial toxicity in skeletal muscle. Presenting features include proximal muscle weakness, muscle pain, and elevated creatine phosphokinase (CPK). Myopathy is uncommon in modern zidovudine practice but was more prominent historically with high-dose zidovudine. Recognition is important because myopathy typically improves with drug discontinuation.

Monitoring approach: routine baseline CPK not required for all patients, but reasonable in patients with pre-existing muscle disease or on other myopathic drugs. Assess muscle symptoms during clinical visits. Check CPK if patient reports new muscle symptoms during therapy. Progressive weakness or substantial CPK elevation warrants zidovudine discontinuation.

Cardiac muscle considerations: cardiac myopathy has been reported rarely with zidovudine. Mechanism presumed similar to skeletal muscle mitochondrial toxicity. Assess for symptoms of cardiac dysfunction in patients with severe zidovudine skeletal myopathy; consider echocardiography if concerns arise.

Lipoatrophy - loss of subcutaneous fat in face, arms, legs, and buttocks - was one of the most stigmatizing complications of the zidovudine era. Zidovudine and other thymidine analog NRTIs (particularly stavudine) directly damage adipocytes through mitochondrial toxicity mechanisms, causing progressive fat loss that is largely irreversible even after drug discontinuation. Modern preference for tenofovir and other non-thymidine NRTIs largely reflects concerns about lipoatrophy.

Prevention through NRTI selection: the most effective lipoatrophy prevention is avoiding zidovudine in patients at high risk (young patients likely to be on prolonged therapy, patients with lean body composition, women who may be at somewhat higher risk). Modern preference for tenofovir alafenamide, abacavir, lamivudine, or emtricitabine as NRTI components essentially eliminates the lipoatrophy concern for new HIV therapy initiations.

Existing patients with lipoatrophy: patients on long-term zidovudine who have developed lipoatrophy typically benefit from switching to non-thymidine NRTIs. This does not reverse established fat loss but prevents further progression. Some patients experience modest fat recovery over years after the switch. Cosmetic interventions may be considered for particularly affected areas.

Hepatic effects during zidovudine therapy include mild transaminase elevations commonly and hepatic steatosis as part of the mitochondrial toxicity spectrum. Severe hepatic events are uncommon with modern zidovudine dosing. HIV/HBV coinfected patients require special consideration because zidovudine does not treat HBV (unlike lamivudine).

Pre-treatment hepatic assessment: comprehensive metabolic panel with hepatic enzymes; HBsAg and anti-HBc screening (mandatory before any HIV therapy); HCV RNA screening; assessment for alcohol use and non-alcoholic fatty liver disease. Baseline abnormalities may warrant hepatology consultation.

Monitoring during therapy: hepatic enzymes at week 4, week 12, and every 3-6 months thereafter. More frequent monitoring in HBV or HCV coinfection. Assessment for symptoms of hepatic dysfunction (jaundice, right upper quadrant discomfort, hepatomegaly). Any concerning findings warrant workup rather than automatic zidovudine attribution.

Digestive effects of zidovudine include nausea, anorexia, and weight loss. Gastrointestinal symptoms are most prominent in the first weeks of therapy and often improve with continued use. Taking zidovudine with food can help reduce nausea. Weight loss during zidovudine therapy is multifactorial and warrants attention when substantial.

When further evaluation warranted: severe abdominal pain (particularly epigastric) warrants pancreatitis workup. Progressive weight loss beyond initial adjustment warrants nutritional and opportunistic infection assessment. Bloody or persistent diarrhea suggests other etiologies. Severe or unexplained symptoms deserve workup rather than assumption of zidovudine effect.

Nutritional support: adequate caloric and protein intake supports HIV therapy tolerance and immune recovery. Registered dietitian consultation is helpful in patients with baseline nutritional concerns or during weight loss episodes. High-quality protein intake particularly important. Alcohol limitation is standard given HIV and potential concomitant HCV.

Neuropsychiatric effects during zidovudine therapy are typically mild. Headache and insomnia are the most common concerns. Cognitive complaints have been reported. Central nervous system effects are generally manageable and improve after the first weeks. Severe neuropsychiatric events are uncommon.

Post-cure/suppression CNS improvement: patients with HIV-associated neurocognitive complaints often experience improvement on effective antiretroviral therapy regardless of specific NRTI selection. HIV suppression benefits CNS function broadly. Zidovudine specifically does not contribute more or less than other NRTIs in this improvement.

Skin effects of zidovudine include distinctive nail pigmentation changes - one of the most characteristic and cosmetically noticeable features of zidovudine therapy. Rash and other cutaneous findings are less common. Nail pigmentation is harmless but often surprising to patients when it develops.

Patient counseling about nail pigmentation: warn patients starting zidovudine that nail discoloration may develop - this prevents surprise or alarm if it occurs. Reassure that the change is harmless. Discuss cosmetic options if the patient is bothered by appearance (nail polish, professional manicures). Emphasize that pigmentation does not indicate treatment problems.

Distinguishing from other causes of nail discoloration: fungal nail infection, melanoma (particularly if a single dark streak), and other drug-induced pigmentation (some antimalarials, chemotherapy) can cause similar findings. Zidovudine nail changes typically affect multiple nails and evolve gradually. Any concerning or asymmetric pigmentation warrants dermatology evaluation.

Metabolic effects during zidovudine therapy include contributions to insulin resistance, dyslipidemia, and the broader HIV lipodystrophy syndrome. These effects reflect combined contributions of chronic HIV, antiretroviral therapy including zidovudine, and other patient factors. Zidovudine specifically appears to contribute to metabolic abnormalities as part of its mitochondrial toxicity spectrum.

Metabolic monitoring during HIV therapy: baseline fasting glucose, lipids, and body composition assessment. Periodic monitoring (typically annually) during ongoing therapy. Standard cardiovascular risk assessment. Diabetes management per standard guidelines when indicated. Lipid management per cardiovascular prevention guidelines.

Modern HIV therapy metabolic advantages: modern integrase inhibitor-based regimens with tenofovir alafenamide backbone have generally favorable metabolic profiles compared to historical zidovudine + efavirenz or zidovudine + PI regimens. Where clinical circumstances allow, switching from zidovudine to modern alternatives may improve metabolic parameters over time.

Cardiovascular considerations during zidovudine therapy relate primarily to the consequences of anemia rather than direct cardiac toxicity. Zidovudine-induced anemia can stress the cardiovascular system, particularly in patients with underlying coronary artery disease. Rare cases of cardiomyopathy have been reported as part of the mitochondrial toxicity spectrum. Understanding these considerations guides monitoring and dose adjustment decisions.

Direct zidovudine cardiac effects are limited: the cardiac concerns are essentially all indirect via anemia or rare mitochondrial cardiomyopathy. Zidovudine does not typically cause direct cardiac toxicity in the sense of QT prolongation, arrhythmia induction, or vasomotor effects. Understanding this distinguishes zidovudine from drugs with intrinsic cardiac effects.

Unstable cardiac disease considerations: patients with unstable coronary syndromes, recent MI, or decompensated heart failure warrant careful evaluation before zidovudine use. Alternative NRTIs may be preferred when clinically appropriate. Cardiology consultation supports individualized decision-making.

HIV resistance to zidovudine involves thymidine analog mutations (TAMs) - a distinctive resistance pattern that emerges under zidovudine (or stavudine) selection pressure. Understanding TAMs and related resistance considerations is important for treatment planning, particularly in patients with prior zidovudine exposure who may need retreatment or alternative NRTI selection.

Resistance testing recommendations: baseline HIV genotype testing at diagnosis is standard practice. Genotype testing before regimen changes after virologic failure is standard. Testing identifies TAMs, M184V, K65R (tenofovir/abacavir resistance), and other relevant mutations that guide regimen selection.

Retreatment considerations after zidovudine failure: patients failing zidovudine-containing regimens typically require full genotype analysis to characterize the resistance profile. Alternative NRTIs (tenofovir, abacavir with HLA-B*5701 testing) may still be options depending on the specific mutations. Third-agent selection (integrase inhibitor typically preferred) should be based on full resistance analysis. Specialist involvement supports appropriate retreatment planning.

Monitoring during zidovudine therapy focuses on bone marrow suppression surveillance, treatment response assessment via HIV RNA, tolerability review, and specific parameters based on individual patient factors. A structured monitoring schedule supports safe therapy delivery and confirms virologic suppression that is the goal of HIV treatment.

Enhanced monitoring scenarios: cardiovascular disease patients need more frequent hemoglobin monitoring; renal impairment patients need enhanced CBC and CMP monitoring; concurrent bone marrow suppressants (chemotherapy, ganciclovir, ribavirin) require weekly CBC initially; pregnancy scenarios need additional pregnancy testing and coordination with maternal-fetal medicine.

Long-term monitoring in modern era: patients on effective HIV therapy for years to decades need continued monitoring for both HIV-related and general health parameters. Cardiovascular risk assessment, cancer screening, bone density in appropriate patients, and other age-appropriate care support comprehensive HIV care in the era where HIV is a chronic manageable condition.

Proper storage and comprehensive patient counseling support safe zidovudine therapy. Counseling for zidovudine covers adherence, warning signs of hematologic toxicity, distinctive adverse effects (nail pigmentation), the specific perinatal HIV prevention context if applicable, and the general framework for HIV therapy including combination requirements.

Vaccinations relevant to HIV patients: HIV-positive patients should be vaccinated against hepatitis A and hepatitis B (if not already immune or infected), pneumococcus, influenza (annually), tetanus/pertussis, HPV where age-appropriate, and other age- and risk-appropriate immunizations. Live vaccines are generally contraindicated in patients with CD4 under 200. Coordination between HIV specialists and primary care supports comprehensive preventive care.

Contraindications for zidovudine include absolute prohibitions for hypersensitivity and specific comorbid conditions, plus relative contraindications requiring careful evaluation. Given zidovudine adverse effect profile and the availability of better-tolerated alternatives for most HIV therapy scenarios, the threshold for using zidovudine has risen substantially in modern practice.

Special populations reminders: pediatric patients from birth can receive zidovudine with weight-based dosing (section 14) - critical for neonatal prophylaxis. Elderly patients tolerate zidovudine with careful monitoring per section 15. Cirrhotic patients require specialist consultation. Pregnancy has extensive zidovudine safety data supporting perinatal use.

When in doubt about appropriateness: consult with HIV specialists. Modern HIV therapy has excellent alternatives to zidovudine for most scenarios. Zidovudine retains specific important applications - perinatal HIV prevention, Combivir fixed-dose combination, resource-limited settings, and specific alternative scenarios. Appropriate patient selection with attention to the contraindications above balances efficacy with tolerability considerations.